Open AccessCase Report of Non-small Cell Lung Cancer Patient with EGFR T790M Mutation Treated with Th ird Generation Inhibitor
Author(s) -
Dinesh Chandra Doval,
Rupal Tripathi,
Kumardeep Dutta Choudhury,
Ajay Sharma,
Ullas Batra,
Anurag Mehta,
Partha S Choudhury
Publication year - 2019
Publication title -
indian journal of medical sciences/indian journal of medical sciences (print)
Language(s) - English
Resource type - Journals
eISSN - 1998-3654
pISSN - 0019-5359
DOI - 10.25259/ijms_9_2019
Subject(s) - t790m , osimertinib , medicine , lung cancer , epidermal growth factor receptor , mutation , cancer research , egfr inhibitors , targeted therapy , oncology , epidermal growth factor , lung , cancer , gene mutation , gene , receptor , genetics , gefitinib , biology , erlotinib
Lung cancer treatment based on the molecular classifi cation of the tumor has paved the way for multiple lines of targeted treatment, even though the development of resistance remains a major cause of concern. Epidermal growth factor receptor (EGFR) remains the poster boy for the use of targeted therapy, and the presence/absence of mutations in this gene has led to the development of inhibitors targeting specifi c mutations. We present the case of an advanced non-small cell lung cancer patient with EGFR T790M mutation treated with Osimertinib, a third-generation inhibitor.